{"entity":{"id":"elucidate-bio","kind":"company","name":"Elucidate Bio","aka":[],"tldr":"Spatial multi-omics service that images DNA, RNA, and protein from the same tissue slide to predict therapeutic response.","summary":"Elucidate Bio, based in Boston, is a spatial multi-omics service that images DNA, RNA and protein from the same tissue slide to predict therapeutic response. It profiles more than eighteen thousand transcripts and forty to sixty protein markers on formalin-fixed sections with full spatial context, offering analytics for trial endpoints and response prediction, and it was founded and is led by Will Singleterry. OnCo links it to single-cell and spatial profiling and to proteomics and phosphoproteomics. Whether spatial multi-omics readouts can be validated as trial endpoints, rather than remaining exploratory, is the open question. The spatial profiling technology page carries the wider field.","asOf":"2026-09-04","links":[{"label":"Products and services","url":"https://elucidatebio.com/products-and-services/"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics","drug-discovery"],"technologies":["single-cell-spatial","proteomics"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Boston, MA","country":"US","companyType":"diagnostics","website":"https://elucidatebio.com","investors":[],"funding":[]},"route":"/companies/elucidate-bio/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"},{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/"}]}}